Sort   by:  
 Page size 
UnknownSustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.
Not available
S-EPMC3940538 | biostudies-literature
ProteomicsSystematic Discovery and Validation of T Cell Targets Directed Against Oncogenic KRAS Mutations
Jaewon Choi, Scott P. Goulding, Brandon P. Conn, Christopher D. McGann, Jared L. Dietze, Jessica Kohler, Divya Lenkala, Antoine Boudot, Daniel A. Rothenberg, Paul J. Turcott, John R. Srouji, Kendra C. Foley, Michael S. Rooney, Marit M. van Buuren, Richard B. Gaynor, Jennifer G. Abelin, Terri A. Addo...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2021-08-13 | MSV000087987 | MassIVE
UnknownAnalysis of variability in the rabbit skin irritation assay.
Not available
S-EPMC8186434 | biostudies-literature
TranscriptomicsRNA-SEQ of epithelioid mouse mesothelioma treated with or without CSF1R inhibitor
Mesothelioma arises in humans after prolonged chronic inflammation driven by the presence of inhaled asbestos fibres in the chest cavity. We have generated a genetically engineered mouse model of mesothelioma that combines CRE-mediated deletion of 3 disease-relevant tumour suppressor genes, namely ...
ORGANISM(S): Mus musculus 
2023-06-03 | E-MTAB-12998 | biostudies-arrayexpress
TranscriptomicsRNA-seq of human breast cancer cell lines MCF7 and T74D naive and resistant to palbociclib treated with capivasertib, fulvestrant and combination
T47D and MCF7 cell lines were treated with long-term (continuous) palbociclib to induce 4 resistant cell-lines (T47D RB-, T47D CDK6H, MCF7 RB- and MCF7 PacqR). Each cell line (both parental and resistant) were then treated with DMSO (control), capivasertib monotherapy, fulvestrant monotherapy and ca...
ORGANISM(S): Homo sapiens 
2023-08-14 | E-MTAB-13262 | biostudies-arrayexpress
ProteomicsDefining HLA-II ligand processing and binding rules with mass spectrometry enhances cancer epitope prediction
Increasing evidence indicates CD4+ T cells can recognize cancer-specific antigens and control tumor growth. However, it remains difficult to predict the antigens that will be presented by human leukocyte antigen class II molecules (HLA-II) - hindering efforts to optimally target them therapeutically...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2019-06-18 | MSV000083991 | MassIVE
UnknownAssociation of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
Not available
S-EPMC5840029 | biostudies-literature
UnknownTherapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
Not available
S-EPMC8362594 | biostudies-literature
UnknownDexmedetomidine- or Clonidine-Based Sedation Compared With Propofol in Critically Ill Patients: The A2B Randomized Clinical Trial.
Not available
S-EPMC12090071 | biostudies-literature
UnknownCost-Effectiveness of α2 Agonists for Intravenous Sedation in Patients With Critical Illness.
Not available
S-EPMC12090026 | biostudies-literature
Sort   by:  
 Page size